IRIS
IRIS Home | Critical Effect Search Results
Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the
RfD, RfC, oral slope factor, or inhalation unit risk.
Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with
organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see
Quick Check: Assessments in Development.
Search Filtered by: Critical Effect = "Nervous"
Number of records: 111
| Chemical Name | CASRN | Exposure Route | Critical Effect | RfD/RfC | RfD/RfC Value |
|---|---|---|---|---|---|
| Acephate | 30560-19-1 | Oral | Inhibition of brain ChE | RFD | 4 x 10 -3 mg/kg-day |
| Acetaldehyde | 75-07-0 | Inhalation | Degeneration of olfactory epithelium | RFC | 9 x 10 -3 mg/m3 |
| Acetochlor | 34256-82-1 | Oral | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | RFD | 2 x 10 -2 mg/kg-day |
| Acrylamide | 79-06-1 | Inhalation | Degenerative nerve changes | RFC | 6 x 10 -3 mg/m3 |
| Acrylamide | 79-06-1 | Oral | Degenerative nerve changes | RFD | 2 x 10 -3 mg/kg-day |
| Acrylic acid | 79-10-7 | Inhalation | Degeneration of the nasal olfactory epithelium | RFC | 1 x 10 -3 mg/m3 |
| Aldicarb | 116-06-3 | Oral | Sweating as clinical sign of AChe inhibition | RFD | 1 x 10 -3 mg/kg-day |
| Aldicarb sulfone | 1646-88-4 | Oral | Brain ChE inhibition in females | RFD | 1 x 10 -3 mg/kg-day |
| Allyl chloride | 107-05-1 | Inhalation | Functional and histological peripheral neurotoxicity | RFC | 1 x 10 -3 mg/m3 |
| Baygon | 114-26-1 | Oral | Mild cholinergic symptoms and RBD ChE inhibition | RFD | 4 x 10 -3 mg/kg-day |
| Benzidine | 92-87-5 | Oral | Brain cell vacuolization; liver cell alterations in females | RFD | 3 x 10 -3 mg/kg-day |
| Biphenthrin | 82657-04-3 | Oral | Tremors | RFD | 1.5 x 10 -2 mg/kg-day |
| Bromomethane | 74-83-9 | Inhalation | Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity | RFC | 5 x 10 -3 mg/m3 |
| Carbofuran | 1563-66-2 | Oral | RBC and plasma cholinesterase inhibition, and testicular and uterine effects | RFD | 5 x 10 -3 mg/kg-day |
| Carbon disulfide | 75-15-0 | Inhalation | Peripheral nervous system dysfunction | RFC | 7 x 10 -1 mg/m3 |
| Chloral hydrate | 302-17-0 | Oral | CNS depression and GI irritation in humans | RFD | 1 x 10 -1 mg/kg-day |
| Chlorine cyanide | 506-77-4 | Oral | Weight loss, thyroid effects, and myelin degeneration | RFD | 5 x 10 -2 mg/kg-day |
| Chlorine dioxide | 10049-04-4 | Oral | Neurodevelopmental effects | RFD | 3 x 10 -2 mg/kg-day |
| Chlorite (sodium salt) | 7758-19-2 | Oral | Neurodevelopmental effects | RFD | 3 x 10 -2 mg/kg-day |
| Chlorobenzilate | 510-15-6 | Oral | Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) | RFD | 2 x 10 -2 mg/kg-day |
| Chloroprene | 126-99-8 | Inhalation | Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively | RFC | 2 x 10 -2 mg/m3 |
| Cyanogen bromide | 506-68-3 | Oral | Weight loss, thyroid effects and myelin degeneration | RFD | 9 x 10 -2 mg/kg-day |
| Danitol | 39515-41-8 | Oral | Tremors | RFD | 2.5 x 10 -2 mg/kg-day |
| 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Oral | Neurobehavioral effects | RFD | 7 x 10 -3 mg/kg-day |
| Demeton | 8065-48-3 | Oral | ChE inhibition, optic nerve degeneration | RFD | 4 x 10 -5 mg/kg-day |
| Dichloroacetic acid | 79-43-6 | Oral | Lesions observed in the testes, cerebrum, cerebellum, and liver. | RFD | 4 x 10 -3 mg/kg-day |
| Dichlorvos | 62-73-7 | Inhalation | Decreased brain cholinesterase activity | RFC | 5 x 10 -4 mg/m3 |
| Dichlorvos | 62-73-7 | Oral | Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males | RFD | 5 x 10 -4 mg/kg-day |
| Dimethoate | 60-51-5 | Oral | Brain ChE inhibition | RFD | 2 x 10 -4 mg/kg-day |
| 2,4-Dimethylphenol | 105-67-9 | Oral | Clinical signs (lethargy, prostration, and ataxia) and hematological changes | RFD | 2 x 10 -2 mg/kg-day |
| 2,4-Dinitrotoluene | 121-14-2 | Oral | Neurotoxicity, Heinz bodies and biliary tract hyperplasia | RFD | 2 x 10 -3 mg/kg-day |
| 1,4-Dioxane | 123-91-1 | Inhalation | Atrophy and respiratory metaplasia of the olfactory epithelium | RFC | 3 x 10 -2 mg/m3 |
| Disulfoton | 298-04-4 | Oral | ChE inhibition, optic nerve degeneration | RFD | 4 x 10 -5 mg/kg-day |
| 1,4-Dithiane | 505-29-3 | Oral | Nasal olfactory lesions | RFD | 1 x 10 -2 mg/kg-day |
| Endrin | 72-20-8 | Oral | Mild histological lesions in liver, occasional convulsions | RFD | 3 x 10 -4 mg/kg-day |
| Ethephon | 16672-87-0 | Oral | Plasma ChE inhibition | RFD | 5 x 10 -3 mg/kg-day |
| Ethion | 563-12-2 | Oral | Plasma cholinesterase inhibition | RFD | 5 x 10 -4 mg/kg-day |
| Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | Oral | Neurotoxicity | RFD | 1 x 10 -5 mg/kg-day |
| Fenamiphos | 22224-92-6 | Oral | ChE inhibition | RFD | 2.5 x 10 -4 mg/kg-day |
| Fonofos | 944-22-9 | Oral | Cholinesterase inhibition, cholinergic symptoms, and increased liver weight | RFD | 2 x 10 -3 mg/kg-day |
| 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Oral | Neurobehavioral effects | RFD | 2 x 10 -4 mg/kg-day |
| Hexachloroethane | 67-72-1 | Inhalation | Neurotoxicity (tremors and ruffled pelt) | RFC | 3 x 10 -2 mg/m3 |
| Hexachlorophene | 70-30-4 | Oral | Swollen salivary glands, status spongiosis in brain and optic nerve | RFD | 3 x 10 -4 mg/kg-day |
| Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Convulsions in F344 rats | RFD | 4 x 10 -3 mg/kg-day |
| 1,6-Hexamethylene diisocyanate | 822-06-0 | Inhalation | Degeneration of olfactory epithelium | RFC | 1 x 10 -5 mg/m3 |
| n-Hexane | 110-54-3 | Inhalation | Peripheral neuropathy (decreased MCV at 12 weeks) | RFC | 7 x 10 -1 mg/m3 |
| 2-Hexanone | 591-78-6 | Inhalation | Motor conduction velocity of the sciatic-tibial nerve | RFC | 3 x 10 -2 mg/m3 |
| 2-Hexanone | 591-78-6 | Oral | Axonal swelling of the peripheral nerve | RFD | 5 x 10 -3 mg/kg-day |
| Hydrogen sulfide | 7783-06-4 | Inhalation | Nasal lesions of the olfactory mucosa | RFC | 2 x 10 -3 mg/m3 |
| Isobutyl alcohol | 78-83-1 | Oral | Hypoactivity and ataxia | RFD | 3 x 10 -1 mg/kg-day |
| Malathion | 121-75-5 | Oral | RBC ChE depression | RFD | 2 x 10 -2 mg/kg-day |
| Manganese | 7439-96-5 | Oral | CNS effects | RFD | 1.4 x 10 -1 mg/kg-day |
| Manganese | 7439-96-5 | Inhalation | Impairment of neurobehavioral function | RFC | 5 x 10 -5 mg/m3 |
| Mepiquat chloride | 24307-26-4 | Oral | Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects | RFD | 3 x 10 -2 mg/kg-day |
| Mercury, elemental | 7439-97-6 | Inhalation | Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction | RFC | 3 x 10 -4 mg/m3 |
| Merphos | 150-50-5 | Oral | Ataxia, delayed neurotoxicity and weight loss | RFD | 3 x 10 -5 mg/kg-day |
| Merphos oxide | 78-48-8 | Oral | Ataxia, delayed neurotoxicity and weight loss | RFD | 3 x 10 -5 mg/kg-day |
| Methamidophos | 10265-92-6 | Oral | ChE inhibition | RFD | 5 x 10 -5 mg/kg-day |
| Methanol | 67-56-1 | Inhalation | Reduced brain weight in rat pups at 6 weeks of age | RFC | 2 x 10 1 mg/m3 |
| Methyl chloride | 74-87-3 | Inhalation | Cerebellar lesions | RFC | 9 x 10 -2 mg/m3 |
| Methyl methacrylate | 80-62-6 | Inhalation | Degeneration/ atrophy of olfactory epithelium (male rats) | RFC | 7 x 10 -1 mg/m3 |
| Methyl parathion | 298-00-0 | Oral | RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs | RFD | 2.5 x 10 -4 mg/kg-day |
| Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Inhalation | Hyperplasia of olfactory epithelium | RFC | 6 x 10 -4 mg/m3 |
| Methylmercury (MeHg) | 22967-92-6 | Oral | Developmental neuropsychological impairment | RFD | 1 x 10 -4 mg/kg-day |
| Methylmercury (MeHg) | 22967-92-6 | Oral | Developmental neuropsychological impairment | RFD | 1 x 10 -4 mg/kg-day |
| 2-Methylphenol | 95-48-7 | Oral | Decreased body weights and neurotoxicity | RFD | 5 x 10 -2 mg/kg-day |
| 3-Methylphenol | 108-39-4 | Oral | Decreased body weights and neurotoxicity | RFD | 5 x 10 -2 mg/kg-day |
| Naled | 300-76-5 | Oral | Brain ChE inhibition | RFD | 2 x 10 -3 mg/kg-day |
| Naphthalene | 91-20-3 | Inhalation | Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively | RFC | 3 x 10 -3 mg/m3 |
| Nitrobenzene | 98-95-3 | Inhalation | Bronchiolization of the alveoli and olfactory degeneration | RFC | 9 x 10 -3 mg/m3 |
| 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Oral | Neurobehavioral effects | RFD | 1 x 10 -4 mg/kg-day |
| Phosmet | 732-11-6 | Oral | Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition | RFD | 2 x 10 -2 mg/kg-day |
| Pirimiphos-methyl | 29232-93-7 | Oral | Transient plasma ChE depression | RFD | 1 x 10 -2 mg/kg-day |
| Propham | 122-42-9 | Oral | Increase in male spleen weight and ChE depression in females | RFD | 2 x 10 -2 mg/kg-day |
| Propionaldehyde | 123-38-6 | Inhalation | Atrophy of olfactory epithelium | RFC | 8 x 10 -3 mg/m3 |
| Propylene glycol monomethyl ether (PGME) | 107-98-2 | Inhalation | Mild reversible sedation | RFC | 2 mg/m3 |
| Pydrin | 51630-58-1 | Oral | Neurological dysfunction | RFD | 2.5 x 10 -2 mg/kg-day |
| Selenious acid | 7783-00-8 | Oral | Clinical selenosis | RFD | 5 x 10 -3 mg/kg-day |
| Selenium and Compounds | 7782-49-2 | Oral | Clinical selenosis | RFD | 5 x 10 -3 mg/kg-day |
| Silver cyanide | 506-64-9 | Oral | Weight loss, thyroid effects, and myelin degeneration | RFD | 1 x 10 -1 mg/kg-day |
| Styrene | 100-42-5 | Inhalation | CNS effects | RFC | 1 mg/m3 |
| 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Oral | Neurobehavioral effects | RFD | 1 x 10 -4 mg/kg-day |
| Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Oral | (See Note) | RFD | 6 x 10 -3 mg/kg-day |
| Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Inhalation | (See Note) | RFC | 4 x 10 -2 mg/m3 |
| Tetrachlorovinphos | 961-11-5 | Oral | Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition | RFD | 3 x 10 -2 mg/kg-day |
| Tetraethyldithiopyrophosphate | 3689-24-5 | Oral | Depressed RBC and plasma cholinesterase activity | RFD | 5 x 10 -4 mg/kg-day |
| Tetrahydrofuran | 109-99-9 | Inhalation | Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) | RFC | 2 mg/m3 |
| Thiram | 137-26-8 | Oral | Neurotoxicity | RFD | 5 x 10 -3 mg/kg-day |
| Toluene | 108-88-3 | Inhalation | Neurological effects in occupationally-exposed workers | RFC | 5 mg/m3 |
| 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | Oral | Psychomotor impairment | RFD | 3 x 10 1 mg/kg-day |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Performance on neurobehavioral tests | RFC | 9 mg/m3 |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Performance on neurobehavioral tests | RFC | 7 mg/m3 |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Performance on neurobehavioral tests | RFC | 7 mg/m3 |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Performance on neurobehavioral tests | RFC | 6 mg/m3 |
| 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Performance on neurobehavioral tests | RFC | 5 mg/m3 |
| 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 6 x 10 -2 mg/m3 |
| 1,3,5-Trimethylbenzene | 108-67-8 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 4 x 10 -2 mg/kg-day |
| 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 2 x 10 -1 mg/m3 |
| 1,3,5-Trimethylbenzene | 108-67-8 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 1 x 10 -2 mg/kg-day |
| 1,2,4-Trimethylbenzene | 95-63-6 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 1 x 10 -2 mg/kg-day |
| 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 6 x 10 -2 mg/m3 |
| 1,2,4-Trimethylbenzene | 95-63-6 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 4 x 10 -2 mg/kg-day |
| 1,2,3-Trimethylbenzene | 526-73-8 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 4 x 10 -2 mg/kg-day |
| 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 6 x 10 -2 mg/m3 |
| 1,2,3-Trimethylbenzene | 526-73-8 | Oral | Decreased pain sensitivity in male Wistar rats | RFD | 1 x 10 -2 mg/kg-day |
| 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 2 x 10 -1 mg/m3 |
| 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Decreased pain sensitivity in male Wistar rats | RFC | 2 x 10 -1 mg/m3 |
| Vinyl acetate | 108-05-4 | Inhalation | Nasal epithelial lesions | RFC | 2 x 10 -1 mg/m3 |
| Xylenes | 1330-20-7 | Inhalation | Impaired motor coordination (decreased rotarod performance) | RFC | 1 x 10 -1 mg/m3 |
| Zinc cyanide | 557-21-1 | Oral | Weight loss, thyroid effects, and myelin degeneration | RFD | 5 x 10 -2 mg/kg-day |
| n-Butanol | 71-36-3 | Oral | Hypoactivity and ataxia | RFD | 1 x 10 -1 mg/kg-day |